Molecular Mechanism Analysis of Jiangtang Xiaozhi Tablets in Treatment of NAFLD

Min HOU; Wen-jing GAO; Yang DU; Pan WANG; Ju-qin PENG; Ya-dong LIN; Fu-zhi ZHANG; Jun-guo REN; Jian-xun LIU

doi:10.13422/j.cnki.syfjx.20202349

您当前的位置：

首页 >

文章列表页 >

Molecular Mechanism Analysis of Jiangtang Xiaozhi Tablets in Treatment of NAFLD

Data Mining | 更新时间：2021-02-09

- Molecular Mechanism Analysis of Jiangtang Xiaozhi Tablets in Treatment of NAFLD
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 5, Pages: 147-157(2021)
- 作者机构：
  
  1.北京中医药大学，北京 100029
  2.中国中医科学院西苑医院基础医学研究所中药药理北京市重点实验室，北京 100091
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20202349
  CLC： R22;R256.4;R96;R28;
- Published：05 March 2021，
  
  Published Online：09 September 2020，
  
  Received：15 June 2020，
- 稿件说明：
扫描看全文
侯敏,高文静,杜阳等.降糖消脂片治疗NAFLD的分子作用机制分析[J].中国实验方剂学杂志,2021,27(05):147-157.

HOU Min,GAO Wen-jing,DU Yang,et al.Molecular Mechanism Analysis of Jiangtang Xiaozhi Tablets in Treatment of NAFLD[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(05):147-157.
侯敏,高文静,杜阳等.降糖消脂片治疗NAFLD的分子作用机制分析[J].中国实验方剂学杂志,2021,27(05):147-157. DOI： 10.13422/j.cnki.syfjx.20202349.

HOU Min,GAO Wen-jing,DU Yang,et al.Molecular Mechanism Analysis of Jiangtang Xiaozhi Tablets in Treatment of NAFLD[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(05):147-157. DOI： 10.13422/j.cnki.syfjx.20202349.

摘要

目的

运用网络药理学和分子对接方法探讨降糖消脂片治疗非酒精性脂肪性肝病（NAFLD）的分子作用机制。

方法

借助中药系统药理学数据库与分析平台（TCMSP），中医药综合数据库（TCMID），中医药百科全书数据库（ETCM）和中药分子机制的生物信息学分析工具（BATMAN-TCM）获取降糖消脂片各药味的化学成分，于SwissTargetPrediction和STITCH数据库预测化学成分的靶点；借助人类基因数据库（GeneCards），在线《人类孟德尔遗传》数据库（OMIM），治疗靶标数据库（TTD）和疾病相关的基因与突变位点数据库（DisGeNET）筛选NAFLD靶点，并与降糖消脂片活性成分的靶点进行交集分析，获得降糖消脂片治疗NAFLD的靶点。借助STRING 11.0构建治疗靶点蛋白质-蛋白质相互作用（PPI）网络，并利用DAVID 6.8对治疗靶点进行富集分析。最后基于分子对接验证降糖消脂片关键成分与核心治疗靶点的作用特征。

结果

降糖消脂片治疗NAFLD的关键成分包括槲皮素、木犀草素、山柰酚、小檗碱、异鼠李素、白桦脂酸、齐墩果酸、熊果酸、芒柄花黄素和己糖醇，核心靶点为丝裂原活化蛋白激酶1（MAPK1），Jun原癌基因（JUN），MAPK3，蛋白激酶B1（AKT1或者Akt1），肿瘤蛋白p53（TP53），E1A结合蛋白P300（EP300），Fos原癌基因（FOS），肿瘤坏死因子（TNF），

-淀粉样前体蛋白（APP）和细胞色素P450家族成员2E1（CYP2E1）。富集分析表明降糖消脂片主要通过外源代谢、氧化还原和胆固醇代谢等生物过程，调节磷脂酰肌醇3-激酶/蛋白激酶B（PI3K/Akt）信号通路，MAPK信号通路，NAFLD及胰岛素信号通路发挥对NAFLD的治疗作用。分子对接结果显示降糖消脂片关键成分与降糖消脂片治疗NAFLD核心靶点有较好的亲和力。

结论

降糖消脂片可通过多种活性成分、多个关键靶点及多种作用途径治疗NAFLD。

Abstract

Objective

To explore the molecular mechanism of Jiangtang Xiaozhi tablets （JTXZT） in the treatment of non-alcoholic fatty liver disease （NAFLD） by means of network pharmacology and molecular docking.

Method

With the help of traditional Chinese medicine （TCM） Systems Pharmacology Database and Analysis Platform （TCMSP）， TCMs Integrated Database （TCMID）， Encyclopedia of TCM （ETCM） and Bioinformatics Analysis Tool for Molecular Mechanism of TCM （BATMAN-TCM）， the chemical compositions of medicinal materials in JTXZT were obtained， the compound targets were predicted in SwissTargetPrediction database and STITCH database. The targets of NAFLD were searched by The Human Gene Database （GeneCards）， Online Mendelian Inheritance in Man （OMIM）， Therapeutic Target Database （TTD） and DisGeNET， and intersection analysis was performed with the targets of the active ingredients to obtain the targets of JTXZT for treatment of NAFLD. Based on STRING 11.0 database， the protein-protein interaction （PPI） network of therapeutic targets was constructed， and the enrichment analysis of therapeutic targets was carried out by DAVID 6.8. Finally， the interaction characteristics of key components and core therapeutic targets of JTXZT for treatment of NAFLD were verified based on molecular docking.

Result

The key components of JTXZT for treatment of NAFLD were quercetin， luteolin， kaempferol， berberine， isorhamnetin， betulinic acid， oleanolic acid， ursolic acid. formononetin and hexitol， and the core targets of JTXZT for treatment of NAFLD were mitogen-activated protein kinase 1 （MAPK1）， Jun proto-oncogene， activator protein-1 （AP-1） transcription factor subunit （JUN）， MAPK3， protein kinase B1 （AKT1 or Akt1）， tumor protein p53 （TP53）， E1A binding protein p300 （EP300）， Fos proto-oncogene， AP-1 transcription factor subunit （FOS）， tumor necrosis factor （TNF），amyloid beta precursor protein （APP） and cytochrome P450 family 2 subfamily E member 1 （CYP2E1）. Biological function and pathway enrichment analysis showed that JTXZT mainly through xenobiotic metabolic process， oxidation-reduction process， cholesterol metabolic process and other biological processes， regulating phosphatidylinositol 3-kinase/protein kinase B （PI3K/Akt） signaling pathway， MAPK signaling pathway， NAFLD and insulin signaling pathway to play a role in the treatment of NAFLD. The results of molecular docking showed that the active components of JTXZT had a good affinity with the core targets of JTXZT for the treatment of NAFLD.

Conclusion

JTXZT treats NAFLD through multiple active components， multiple key targets and multiple action pathways.

关键词

网络药理学分子对接降糖消脂片非酒精性脂肪性肝病（NAFLD）槲皮素丝裂原活化蛋白激酶（MAPK）磷脂酰肌醇3-激酶/蛋白激酶B（PI3K/Akt）

Keywords

network pharmacologymolecular dockingJiangtang Xiaozhi tabletsnon-alcoholic fatty liver disease （NAFLD）quercetinmitogen-activated protein kinase （MAPK）phosphatidylinositol 3-kinase/protein kinase B （PI3K/Akt）

references

步宏，李一雷.病理学［M］.9版.北京：人民卫生出版社，2018：386.

SIVELL C.Nonalcoholic fatty liver disease：a silent epidemic［J］.Gastroenterol Nurs，2019，42（5）：428-434.

KO J S.New perspectives in pediatric nonalcoholic fatty liver disease：epidemiology，genetics，diagnosis，and natural history［J］.Pediatr Gastroenterol Hepatol Nutr，2019，22（6）：501-510.

HARTLEY A，SANTOS-FERREIRA D L，ANDERSON E L，et al.Metabolic profiling of adolescent non-alcoholic fatty liver disease［J］.Wellcome Open Res，2019，3：166.

AHADI S，GHAREKHANI A，SHIVA A.Treatments of nonalcoholic fatty liver disease in adults who have no other illness：a review article［J］.Arab J Gastroenterol，2019，20（4）：189-197.

ZHANG M，YUAN Y，ZHOU W J，et al.Network pharmacology analysis of Chaihu Lizhong Tang treating non-alcoholic fatty liver disease［J］.Comput Biol Chem，2020，86：107248.

李峰，罗水荣，曾如雪，等.施维群教授辨治非酒精性脂肪肝经验浅析［J］.天津中医药大学学报，2020，39（1）：27-29.

吕锦珍，徐拥建，胡世平，等.参苓白术散对NAFLD大鼠肝细胞mTORC1/STAT3信号通路的影响［J］.中国实验方剂学杂志，2020，26（2）：6-12.

陈筑红，张广德，魏子孝，等.降糖消脂颗粒对2型糖尿病气阴两虚，痰瘀互阻患者的影响［J］.中国中西医结合杂志，2018，38（5）：544-548.

CHEN Z H，XIA C D，WEI Z X.Treatment of type 2 diabetes mellitus patients of qi-yin deficiency phlegm-stasis inter-obstruction syndrome by jiangtang Xiaozhi capsule and pioglitazone tablet：a non-inferiority randomized controlled trial［J］.Chin J Integr Med，2014，34（9）：1042-1046.

CHEN Z H，XIA C D，WEI Z X.Clinical study of Jiangtang Xiaozhi capsule in treating type 2 diabetes mellitus patients［J］.Chin J Integr Med，2012，32（7）：910-913.

SONG W，YUAN Y，YU N，et al.Antioxidant capacity of extract from Jiangtang Xiaozhi recipe in vitro［J］.J Tradit Chin Med，2020，40（3）：393-400.

金龙，葛争艳，董小霞，等.降糖消脂片对肥胖大鼠模型的影响［J］.世界中医药，2018，13（1）：5-11.

葛争艳，金龙，郭宇洁，等.降糖消脂片对胰岛素抵抗大鼠的实验研究［J］.中国实验方剂学杂志，2013，19（24）：218-222.

JIANG Y Y，LIU N，ZHU S R，et al.Elucidation of the mechanisms and molecular targets of Yiqi Shexue formula for treatment of primary immune thrombocytopenia based on network pharmacology［J］.Front Pharmacol，2019，10：1136.

QU Y，ZHANG Z，LU Y，et al.Network pharmacology reveals the molecular mechanism of Cuyuxunxi prescription in promoting wound healing in patients with anal fistula［J］.Evid Based Complement Alternat Med，2019，2019：3865121.

CLYNE A，YANG L P，YANG M，et al.Molecular docking and network connections of active compounds from the classical herbal formula Ding Chuan Tang［J］.PeerJ，2020，8：e8685.

XU X，ZHANG W，HUANG C，et al.A novel chemometric method for the prediction of human oral bioavailability［J］.Int J Mol Sci，2012，13（6）：6964-6982.

RU J L，LI P，WANG J N，et al.TCMSP：a database of systems pharmacology for drug discovery from herbal medicines［J］.J Cheminform，2014，6：13.

SHENG S，YANG Z X，XU F Q，et al.Network pharmacology-based exploration of synergistic mechanism of guanxin Ⅱ Formula （Ⅱ） for coronary heart disease［J］.Chin J Integr Med，2020，doi：10.1007/s11655-020-3199-zhttp://dx.doi.org/10.1007/s11655-020-3199-z.

QU Y J，ZHEN R R，ZHANG L M，et al.Uncovering the active compounds and effective mechanisms of the dried mature sarcocarp of Cornus officinalis Sieb. Et Zucc. for the treatment of Alzheimer's disease through a network pharmacology approach［J］.BMC Complement Med Ther，2020，20（1）：157.

BARDOU P，MARIETTE J，ESCUDIÉ F，et al.Jvenn：an interactive Venn diagram viewer［J］.BMC Bioinformatics，2014，15（1）：293.

HSIN K Y，GHOSH S，KITANO H.Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology［J］.PLoS One，2013，8（12）：e83922.

GAILLARD T.Evaluation of AutoDock and AutoDock Vina on the CASF-2013 benchmark［J］.J Chem Inf Model，2018，58（8）：1697-1706.

郑咏秋，葛争艳，金龙，等.降糖消脂片对KK-Ay糖尿病肥胖小鼠胰岛素受体及底物表达的影响［J］.中国实验方剂学杂志，2013，19（3）：175-179.

葛争艳，金龙，杨斌，等.降糖消脂片对KK-Ay转基因小鼠胰岛素抵抗的影响［J］.中国中西医结合杂志，2017，37（3）：331-337.

刘晟文，刘建英.槲皮素药理学作用的研究进展［J］.中华肺部疾病杂志：电子版，2020，13（1）：104-106.

ZHU X H，XIONG T，LIU P Y，et al.Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway［J］.Food Chem Toxicol，2018，114：52-60.

GENTILE D，FORNAI M，PELLEGRINI C，et al.Luteolin prevents cardiometabolic alterations and vascular dysfunction in mice with HFD-induced obesity［J］.Front Pharmacol，2018，9：1094.

HOANG M H，JIA Y，MOK B，et al.Kaempferol ameliorates symptoms of metabolic syndrome by regulating activities of liver X receptor-β［J］.J Nutr Biochem，2015，26（8）：868-875.

LU Z S，HE B H，CHEN Z Y，et al.Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway［J］.BMC Immunol，2020，21（1）：28.

GU M，ZHAO P，ZHANG S，et al.Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice［J］.Br J Pharmacol，2019，176（7）：847-863.

KWON E Y，SHIN S K，CHOI M S.Ursolic acid attenuates hepatic steatosis，fibrosis，and insulin resistance by modulating the circadian rhythm pathway in diet-induced obese mice［J］.Nutrients，2018，10（11）：1719.

朱宁，原继荣，王德莹.c-fos和c-jun与癌症关系的研究进展［J］.中国优生与遗传杂志，2012，20（2）：6-7，116.

彭孟云，朱晓宁，汪静.MAPK信号通路与非酒精性脂肪肝关系的研究进展［J］.广东医学，2015，36（5）：804-806.

王雨，郝洁，李婕，等.AKT信号通路参与并介导了虎杖苷对2型糖尿病大鼠糖脂代谢的影响［J］.中药药理与临床，2016，32（2）：50-53.

PISONERO-VAQUERO S，MARTÍNEZ-FERRERAS Á ，GARCÍA-MEDIAVILLA M V，et al.Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease［J］.Mol Nutr Food Res，2015，59（5）：879-893.

ABDOLLAHI H，AZODI M Z，HATAMI B.Protein interaction mapping interpretation of none alcoholic fatty liver disease model of rats after fat diet feeding［J］.Gastroenterol Hepatol Bed Bench，2017，10（Suppl1）：S146-S153.

ENGSTLER A J，AUMILLER T，DEGEN C，et al.Insulin resistance alters hepatic ethanol metabolism：studies in mice and children with non-alcoholic fatty liver disease［J］.Gut，2016，65（9）：1564-1571.

王健，姜曼，辛永宁，等.内质网应激在非酒精性脂肪性肝病发病机制中的作用［J］.临床肝胆病杂志，2014，30（11）：1229-1232.

SUNNY N E，BRIL F，CUSI K.Mitochondrial adaptation in nonalcoholic fatty liver disease：novel mechanisms and treatment strategies［J］.Trends Endocrinol Metab，2017，28（4）：250-260.

MARÉCHAL L，LAVIOLETTE M，RODRIGUE-WAY A，et al.The CD36-PPARγ pathway in metabolic disorders［J］.Int J Mol Sci，2018，19（5）：1529.

MORÁN-SALVADOR E，LÓPEZ-PARRA M，GARCÍA-ALONSO V，et al.Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts［J］.FASEB J，2011，25（8）：2538-2550.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Treatment of Diabetic Rats Mellitus-induced Erectile Dysfunction by Xiaoyaosan Based on Experiments

Mechanism of Sanhuang Xiexintang in Protecting Stress Gastric Ulcer in Rats

Mechanism of Cuscutae Semen to Control Premature Ovarian Failure Based on Lipid and Atherosclerosis Pathways

Effect and Mechanism of Zuojinwan on DSS-induced Ulcerative Colitis

Mechanism of Modified Zhenwutang in Delaying Progression of Chronic Renal Failure Based on Network Pharmacology， Molecular Docking， and Experimental Verification

Related Author

MAO Yinhui

WANG Zhuo

SUN Juntao

WEI Zhitao

WANG Mingxing

YANG Yong

ZHONG Yilin

XIE Ran

Related Institution

Changchun University of Chinese Medicine

The Affiliated Hospital of Changchun University of Chinese Medicine

School of Pharmacy， Anhui University of Chinese Medicine

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

School of Basic Medical Sciences，Hubei University of Chinese Medicine

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰